UChicagoCancerCenter

Proud to share our new @Nature study: We developed the 1st NNMT inhibitor that reprograms cancer-associated fibroblasts, boosting immune response & stopping tumor growth in ovarian cancer models, especially when paired with immunotherapy. @OvCa_UChicago nature.com/articles/s4158…

In a new @Nature study, Heide et al., show that blocking NNMT in tumor-supporting cells restores immune response & stops ovarian cancer growth, offering a new strategy for hard to treat cancers. @OvCa_UChicago @uchicago_obgyn @JannaHeide @ErnstLengyel ow.ly/IJIG50WuIQE

New in @Nature: Drs. @ErnstLengyel, @JannaHeide, @OvCa_UChicago & team discovered a first-of-its-kind NNMT inhibitor that reprograms cancer-associated fibroblasts & restores immune response in ovarian cancer, marking a major step toward better therapies. nature.com/articles/s4158…

New in @Nature from our lab: We’ve discovered a first-of-its-kind NNMT inhibitor that reprograms cancer-associated fibroblasts and restores immune response in ovarian cancer—a major step toward more effective therapies. @ErnstLengyel @JannaHeide nature.com/articles/s4158…

🔥 Hot off the press: In a new @Nature study, @ErnstLengyel and team show that blocking NNMT in tumor-supporting cells restores immune response & stops ovarian cancer growth, offering a new strategy for hard to treat cancers. @OvCa_UChicago @uchicago_obgyn ow.ly/zzfZ50Wu3UW

UChicago Medicine’s Bone and Soft Tissue Cancer Program delivers expert, comprehensive care for sarcoma patients. Learn more about our services and support: ortho.uchicago.edu/programs/bone-… #UChicagoMedicine #SarcomaAwareness #BoneCancer #CancerTreatment #OrthopaedicSurgery

Bone cancer is rare—fewer than 1% of cancers. About 3,500 new U.S. cases each year. Early diagnosis can change lives. Learn more on statistics and facts: seer.cancer.gov/statfacts/html… #BoneCancerAwareness #CancerStatistics #FightCancer #CancerEducation

Meet UChicago’s Bone & Soft Tissue Cancer physician team—leaders in sarcoma treatment and research.uchicagomedicine.org/cancer/types-t… #UChicagoMedicine #CancerCare #BoneCancerAwareness

In Chicagoland and need a ride to your appointment? Sisters Working It Out offers FREE transportation for cancer patients. Call: 708-932-9761 Or email: [email protected] #CancerSupport #Chicagoland #HealthcareAccess

Symptoms like persistent fever, fatigue, or weight loss can be signs of bone cancer. Know the signs. More info: cdc.gov/nceh/radiation…

Join the AACR this month to support those impacted by sarcoma and bone cancers. Get involved: aacr.org/patients-careg… #SarcomaAwareness #BoneCancerAwareness #AACR #CancerSupport #AwarenessMonth

Enjoy the summer safely! ☀️ UV rays increase cancer risk. Wear SPF, reapply, and cover up. Your skin will thank you. #UVAwareness #CancerPrevention

The American Childhood Cancer Organization (ACCO) supports children with sarcoma and their families. Learn how you can help: acco.org/sarcoma-awaren… #SarcomaAwareness #ChildhoodCancer #BoneCancerAwareness #ACCO #CancerSupport #AwarenessMonth

Bone cancer often affects long bones—but can occur in any bone. Know the signs, stay proactive. Learn more: cancer.org/cancer/types/b…. #BoneCancerAwareness #CancerEducation

Early signs of sarcoma: pain, swelling, or unexplained lumps. Early detection = better outcomes. Learn more: cancer.org/cancer/types/b… #SarcomaAwareness #BoneCancerAwareness #EarlyDetection (image by Verywell Health)

Join us for the Neuroendocrine Tumor Research Foundation's Know Your NETs Virtual Patient and Caregiver Conference. This online event will be held July 26th and offers the latest updates on treatments, cutting-edge research and more. netrf.org/for-patients/2…

Patients with progressive TP53-mutant CH clones progressed to therapy-related ALL or myeloid neoplasms, while stable clones had lower leukemogenic potential. The data suggest that serial monitoring is more informative than cross-sectional assessment of CH in pts receiving MM tx.

To understand the impact of lenalidomide on evolution of therapy-related CH, we studied prospectively obtained samples from two major MM trials (ATLAS and MRD2STOP), run by @bdermanmd, Andrzej Jakubowiak and Jen Cooperrider.

Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN. Can we predict the risk for second blood cancer in myeloma pts? Grateful for the collaboration with @UCCancerCenter myeloma program. nature.com/articles/s4137…

Join renowned faculty in Chicago to discover the transformative potential of cellular therapies for hematologic malignancies, solid tumors, & non-oncologic conditions. Register now for the Jonas Center Cellular Therapy Symposium! 👉 cme.uchicago.edu/JCCTS2025 @UCCancerCenter #CME